Spencer Sung Bum Huh, BEc.
Director, President and Chief Executive OfficerMr. Spencer Sung Bum Huh graduated from the Korea University in Seoul with a BEc. He is an experienced and proven financial professional with more than 25 years of financial and operational experience in Canada and Korea, and a track record of supporting ambitious growth plans. His expertise includes financial operations, strategy, performance management, and business planning for Korean and Canadian companies.Mr. Huh began his career in 1993 as an investment advisor with Hanwha securities in Korea. After immigration to Canada in 2000, he served for 6 years as an investment advisor with BMO Nesbitt Burns in Toronto and, subsequently, he joined TD Canada Trust in Vancouver. Since 2012, Mr. Huh worked with numerous private and publicly listed companies in Korea and Canada, including mining, medical device, and high-tech companies. He has played an integral role in the establishment, acquisitions, and financing for these companies.
Sung Rock Hwang
Mr. Sung Rock Hwang has over 30 years’ experience working for Samsung SDI, serving as the executive director and chief of purchasing, senior manager, general manager (for the German branch), and advisor until 2018. His responsibilities included managing the supply chain, procurement planning, and advanced business development.
During his time with Samsung SDI, Mr. Hwang accumulated a vast network and information pipeline within the lithium ion battery industry. He has a deep understanding of business development and trade capabilities, as well a specialized knowledge in raw materials, such as cobalt, nickel, and aluminum.
Director, Vice President of Corporate Finance
Mr. Chris Chung received his honors bachelor’s degree with a double major in statistics and economics at the University of Toronto and has been a registrant with Canadian securities commissions since 2005. In addition, he has fulfilled numerous curricula, including, among others, Derivatives Fundamentals Course (DFC), Options Licensing Course (OLC), Professional Financial Planner (PFP) and Life License Qualification Program (LLQP).
Mr. Chung has been a licensed equity and derivative trader at Merrill Lynch Securities in Toronto, an investment representative of HSBC Securities (Canada), a regional manager (Western Canada) of Walton Capital Management in Calgary, vice-president of corporate sales for Triview Capital Ltd. for both British Columbia and Ontario, and vice-president, finance, for Ascenta Finance Ltd. (an independent Canadian institutional investment bank headquartered in Vancouver).
Mr. Chung has over 12 years of banking and wealth management experience specializing in both the private and public equities sector. During his career, Mr. Chung has raised more than $100-million in private equity.
Gun Min Park
Vice President of Corporate Strategies
Mr. Park received his Economics and Applied Statistics as a double degree (Financial Engineering Program) with Honours at Yonsei University in South Korea and has obtained his Certified Financial Planner designation in Canada. Over the past 13 years, Mr. Park has accumulated substantial experience with asset management.
Mr. Park has expertise in the specialized field of Corporate ownership and estate and tax planning through the organization of optimal corporation structures. He has also been working with individuals as a financial advisor, providing alternative investment strategies and implementing and recommending the appropriate financial products to ensure proper customized financial planning. Mr. Park works with an extensive network of professional advisors (accountants, lawyers, and private corporation owners among others) across Canada and throughout South Korea and the rest of Asia.
Larry Okada, CA, CPA, (Wash.)
Mr. Larry Okada has been involved with a number of public mining companies for 36 years. He is a Chartered Accountant and has been in public practice since 1974 with extensive public finance and accounting experience with Deloitte and Touche, Staley Okada and Partners and PricewaterhouseCoopers LLP.
Mr. Okada presently serves as the Chief Financial Officer (“CFO”) for RedQuest Capital Corp (CPC) and is the Acting CFO of Africo Resources Ltd. as well as being a director and serving as chairman of the audit committee of Forum Uranium Corp. and Revett Minerals Corp.
John Kowalchuk, P. Geo.
Mr. John Kowalchuk is a professional geoscientist with the Association of Engineers and Geoscientists of British Columbia. Presently he is Project Manager for Golden Reign Resources Ltd. developing a high– grade gold resource in Nicaragua. He has over 43 years of experience developing and managing exploration projects with both senior and junior mining companies and has worked in Canada, the United States, Russia, Mexico, Chile and Nicaragua.
Mr. Kowalchuk was Yukon and Northern B. C. District Geologist for Placer Dome Inc., during which time he was instrumental in the discovery and advancement of several world–class mineral deposits, including the Howard’s Pass lead–zinc deposits and the Kerr copper–gold porphyry deposit.
Mr. Kowalchuk was directly responsible for the discovery of the barium–lead–zinc–silver deposit in Driftpile Creek, and the discovery and exploration management of the Clea Tungsten property, which has the potential to become a significant tungsten mine in northern Canada.
Nancy Zhao, CPA
Chief Financial Officer
Ms. Zhao is a CPA with over nine years experience with both public and private companies.
Ms. Zhao has experience in accounting and finance for various industries, including mining, Realtor development, property management, sports entertainment, marketing and farming.
She also currently holds the position of chief financial officer of Blox Inc. (BLXX) and Ashanti Sankofa Inc. (TSX Venture Exchange: ASI), both are publicly listed mining companies based in Vancouver, B.C.
Su Jun Park
Mr. Park brings his strong marketing and finance background to the advisory board. Mr. Park has worked in the pharmaceutical industry for over 30 years, providing marketing, sales and business development experience to various companies.
Mr. Park started his career with Pfizer Korea, before moving on to MSD Korea, where he was national sales manager. While heading sales and strategic planning at Boehringer Ingelheim Korea, Mr. Park helped successfully launch Trajenta (diabetes medication, 2011), Pradaxa (anti-coagulant, 2011) and Twynsta (anti-hypertension, 2010) in Korea for Boehringer Ingelheim. Mr. Park helped grow sales at an average rate of 18 per cent per year.
From 2012 to 2016, Mr. Park was general manager at Sandoz Korea, a division of Novartis, where he helped to more than double revenue, $15-million (U.S.) (2012) to $35-million (U.S.) (2016).
Most recently, Mr. Park was chief executive officer and president of (March, 2016, to April, 2018), and then, consultant to Yungjin Pharmaceuticals,
a publicly listed company trading on the Korean Stock Exchange with a market cap of $1-billion (U.S.). During his tenure as CEO, Mr. Park accomplished numerous research milestones, licensing agreements and a merger with KT&G Life Sciences, a subsidiary of KT&G Corp., South Korea’s largest tobacco and ginseng product manufacturer.
Dr. Dongmok Whang
Dr. Dongmok Whang received a PhD degree in Chemistry from the Pohang University of Science and Technology in Korea (POSTECH) in 1997. Prior to joining SKKU, he was a Senior Research Fellow at Harvard University (2001—2004) and a Postdoctoral Research Associate at (POSTECH) (1997—2001). As Associate Professor at Harvard, Dr. Whang was a member of the Lieber Research Group focused broadly on science and technology at the nanoscale, harnessing the unique physical properties of novel nanomaterials. He has also co-authored over 120 peer-reviewed publications, such as Science Magazine, with about 10,000 citations.
Dr. Whang is a Professor at the School of Advanced Materials Science & Engineering and Advanced Institute of Nanotechnology, Sungkyunkwan University (SKKU), Korea. His research interest is in controlled fabrication of low-dimensional nanomaterials, such as graphene, semiconductor nanowires,porous nanostructures, and hybrid nanostructures for various electronic and energy applications including rechargeable batteries, fuel cells, and flexible optoelectronic devices (OLED), among others.
Dr. Whang is a co-leader of a joint research team of Samsung Electronics (Samsung) and SKKU that last year has developed
an original technology to create a new material by synthesizing amorphous graphene for the first time in the world. This new
material has low conductivity, which expands the use of graphene from the electronics industry to others, including desalination.
Dr. Whang and Hwang Sung-woo, managing director of Nanoelectronics Lab Team at Samsung, jointly developed the technology to synthesize the large-area monatomic amorphous graphene called “dream material”.
Dr. Whang owns more than 50 patents, one third of which is co-owned with Samsung Electronics. He is the leader of Functional
Nanomaterial Lab at SKKU and supervises two post-doctoral fellows, as well as 17 students, with 15 students on doctoral level.
The Lab is financed by grants from both, the Korean government and Samsung.
Ki-Tae Robert Lee
Mr. Lee brings his strong capital markets background to the advisory board.
After serving in the Korean air force for three years, Mr. Lee joined Hanwha Investment & Securities and Hanwha Life Insurance (affiliates of Hanwha Corp.) where he has spent the last 25 years.
Beginning his career as a trader, Mr. Lee executed and handled settlement of equity trades for overseas clients, managed portfolios for institutional investors ($600-million under management), and managed financial assets as a branch manager at various locations in Seoul.
In 2008, Mr. Lee was awarded the title of one of Korea’s top 50 portfolio managers. Mr. Lee finished his career at Hanwha as an executive officer of the company.
Dr. Jay Han
Dr. Han has worked with biomedical companies for over 20 years, driving research and development, product innovation and technology commercialization in the United States and Korea.
He has led product development and project management in life sciences/in vitro diagnostics, focusing on microfluidic technology and point-of-care testing in vitro diagnostics (IVD) applications.
He served a pivotal role in growing the companies and positioning them for successful acquisition based and initial public offering based exits. Dr. Han specializes in R&D and innovation management, product commercialization, and strategic positioning. He also offers the expertise to search, define, validate and execute new business models and partnerships that bridge the gaps between early-stage technology, R&D and manufacturing, and life sciences/IVD industries.
Dr. Han earned his official certificate of PMP (project management professional) showing his fully demonstrated understanding and in-depth knowledge and skills to lead/direct various projects. In Siloam, he built up a quality management system (QMS) pursuing a Food and Drug Administration-qualified facility under a QSR (quality system regulation) for medical devices. Dr. Han obtained his PhD degree with a specialty in MEMS (microelectric mechanical systems) and BioMEMS from the department of electrical and computer engineering and computer science at University of Cincinnati.
Dr. Doo Jae Min
Dr. Min has over 18 years of experience in both academia and the business world, acting as chief executive officer of medical device and cosmetic companies. Dr. Min is currently a professor at the department of anesthesiology and pain medicine at the Korea University Medical School. Dr. Min is a member of both the American Society of Anesthesiologists and the Korean Society of Anesthesiologists. Dr. Min is a member of the medical device standard development committee in Korea and has co-written over 50 peer-reviewed publications for which he has received over 5,000 citations.
Dr. Min has been awarded multiple prizes in his scientific field, including: Dong-Soong Best Scientist Award (2011), Best Anesthesia and Pain Medicine Article of the Year (2016), and Best Artificial Intelligence Application in the medical field (2018). Dr. Min received his PhD in medical science from the Graduate School of Korea University (Seoul, Korea) in 2010 and his postgraduate from the Business School of Korea University (advanced management program) in February, 2018.